Home › Trial NCT04895761
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
- Trial IDNCT04895761
- StatusActive Not Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorProvidence Health & Services
- Enrollment6
- Start date2021-09-10
- ConditionsBreast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.